Atrium Therapeutics, Inc. (RNA)
7.84
-0.30
(-3.69%)
USD |
NASDAQ |
Oct 02, 16:00
7.98
+0.14
(+1.79%)
After-Hours: 20:00
Atrium Therapeutics Net Income (Quarterly) : -20.19M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -20.19M |
| March 31, 2026 | -16.63M |
| December 31, 2025 | -29.14M |
| Date | Value |
|---|---|
| June 30, 2025 | -12.88M |
| March 31, 2025 | -7.449M |
| December 31, 2024 | -11.51M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Tenax Therapeutics, Inc. | -17.80M |
| Exicure, Inc. | -1.121M |
| Century Therapeutics, Inc. | -34.55M |
| Absci Corp. | -33.21M |
| Celularity, Inc. | 0.675M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 3.004M |
| Total Expenses (Quarterly) | 23.19M |
| EPS Diluted (Quarterly) | -1.18 |
| Enterprise Value | -128.42M |
| Gross Profit Margin (Quarterly) | 88.58% |
| Profit Margin (Quarterly) | -672.0% |
| Earnings Yield | -58.77% |
| Normalized Earnings Yield | -58.77 |